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Emerging evidence suggests that transforming growth factor-b
(TGF-b) is an important mediator of diabetic nephropathy. We
showed previously that short-term treatment with a neutralizing
monoclonal anti-TGF-b antibody (aT) in streptozotocin-diabetic
mice prevents early changes of renal hypertrophy and increased
matrix mRNA. To establish that overactivity of the renal TGF-b
system mediates the functional and structural changes of the more
advanced stages of nephropathy, we tested whether chronic
administration of aT prevents renal insufficiency and glomerulo-
sclerosis in the dbydb mouse, a model of type 2 diabetes that
develops overt nephropathy. Diabetic dbydb mice and nondiabetic
dbym littermates were treated intraperitoneally with aT or control
IgG, 300 mg three times per week for 8 wk. Treatment with aT, but
not with IgG, significantly decreased the plasma TGF-b1 concen-
tration without decreasing the plasma glucose concentration. The
IgG-treated dbydb mice developed albuminuria, renal insuffi-
ciency, and glomerular mesangial matrix expansion associated
with increased renal mRNAs encoding a1(IV) collagen and fibronec-
tin. On the other hand, treatment with aT completely prevented
the increase in plasma creatinine concentration, the decrease in
urinary creatinine clearance, and the expansion of mesangial
matrix in dbydb mice. The increase in renal matrix mRNAs was
substantially attenuated, but the excretion of urinary albumin
factored for creatinine clearance was not significantly affected by
aT treatment. We conclude that chronic inhibition of the biologic
actions of TGF-b with a neutralizing monoclonal antibody in dbydb
mice prevents the glomerulosclerosis and renal insufficiency re-
sulting from type 2 diabetes.
D iabetic nephropathy, a common complication in patientswith either type 1 or type 2 diabetes mellitus, has long been
recognized to cause severe morbidity and mortality. The renal
structural alterations in susceptible patients are characterized by
the early appearance of hypertrophy in glomerular and tubular
components, the subsequent development of thickened glomer-
ular and tubular basement membranes (but with enhanced
glomerular permeability to albumin), and the progressive accu-
mulation of extracellular matrix components in the glomerular
mesangium and tubulointerstitium. Glomerulosclerosis and tu-
bulointerstitial fibrosis are the structural hallmarks of advanced
diabetic nephropathy with renal insufficiency (1, 2).
In experimental animal models of diabetic kidney disease,
there is increased gene expression and protein synthesis of
several extracellular matrix components, such as type IV colla-
gen, laminin, and fibronectin, in renal cortical specimens and
isolated glomeruli (reviewed in ref. 3). In vitro studies provide
evidence that high ambient glucose increases the synthesis of
extracellular matrix in all glomerular cell types (4–7). In general,
hyperglycemia exerts its adverse effects in the kidney by acti-
vating enzymatic pathways for glucose metabolism (8–11), non-
enzymatically glycosylating circulating or tissue proteins (12, 13),
and altering the responsiveness to vasoactive hormones or locally
generated cytokines or growth factors (3, 14, 15).
Several in vitro and in vivo studies implicate transforming
growth factor-b (TGF-b) in the pathogenesis of diabetic kidney
disease (reviewed in ref. 16). This cytokine acts in autocrine or
paracrine fashion to elicit profound effects on cell growth and
extracellular matrix accumulation. Production of the TGF-b
isoforms (-1, -2, and -3) and expression of the TGF-b receptors
(types I, II, and III) are typically found in renal cell types exposed
to diabetic conditions. TGF-b1 mRNA and protein levels are
significantly increased in the kidney cortex of type 1 diabetic
animals such as the spontaneously diabetic BioBreeding rat, the
nonobese diabetic mouse (17), and the streptozotocin (STZ)
diabetic rat (18–20) or mouse (21). The type II receptor for
TGF-b is concomitantly up-regulated in the kidney of STZ
diabetic mice (21) and type 2 diabetic dbydb mice (22). Patients
with diabetic nephropathy also demonstrate up-regulated
TGF-b1 mRNA and protein in the glomerulus (23, 24) and
tubulointerstitium (23). In fact, the diabetic kidney is capable of
net TGF-b1 synthesis as seen in our study demonstrating sig-
nificantly greater TGF-b1 levels in the renal vein vs. the artery
and increased TGF-b1 protein excreted in the urine of diabetic
compared with nondiabetic patients (25).
The biologic effects of the TGF-b system in kidney cells most
closely resemble those of hyperglycemia, which include cellular
hypertrophy and stimulation of extracellular matrix production
(26). We have reported that tubular epithelial cells, glomerular
mesangial cells, and interstitial fibroblasts (27–30) significantly
increase their TGF-b1 expression and bioactivity when cultured
in high ambient glucose. Additionally, neutralizing anti-TGF-b
antibodies prevent the stimulation of collagen biosynthesis by
high glucose in tissue culture (7, 30). To assess the functional role
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of the TGF-b system in the early manifestations of diabetic renal
disease, we previously evaluated the feasibility and efficacy of
administering a neutralizing anti-TGF-b antibody over a 9-day
period to STZ diabetic mice (21). We found increased produc-
tion of TGF-b1 and up-regulation of the TGF-b type II receptor
in the diabetic kidney, preceding the onset of renal hypertrophy.
Inhibition of TGF-b activity prevented glomerular enlargement
and attenuated the increase in the mRNAs encoding a1(IV)
collagen and fibronectin (21).
However, none of the cited studies has established a direct
causal link between increased activity of the renal TGF-b system
and the more advanced clinical manifestations of diabetic ne-
phropathy such as glomerulosclerosis, proteinuria, and renal
insufficiency. To address this question, we have resorted to an
experimental model of overt diabetic nephropathy that closely
resembles the human disease. We therefore tested the effective-
ness of long-term administration of neutralizing anti-TGF-b
antibodies in preventing glomerulosclerosis and renal insuffi-
ciency in diabetic dbydb mice. An 8-wk treatment period signif-
icantly depressed plasma TGF-b1 levels and prevented renal
insufficiency, excess matrix expression, and expansion in the
glomerular mesangium. This is, to our knowledge, the first
proof-of-concept study to provide strong support for the premise
that chronic inhibition of the biologic actions of TGF-b in the
kidney effectively prevents renal failure resulting from diabetes.
Methods
Experimental Animals. The dbydb mouse, lacking the hypotha-
lamic leptin receptor (31), is a model of type 2 (noninsulin-
dependent) diabetes mellitus that exhibits hyperglycemia,
hyperinsulinemia, and hyperleptinemia associated with hy-
perphagia and obesity manifesting around 4–7 wk after birth
(32). The therapeutic intervention was started at 8 wk of age
because 100% of the dbydb genotype become frankly hypergly-
cemic (12). One group of dbydb mice (n 5 9, dbydb-aT) and one
group of nondiabetic dbym littermates (n 5 9, dbym-aT) were
treated with a murine monoclonal antibody (aT) that neutralizes
all three mammalian TGF-b isoforms (-b1, -b2, and -b3) (33).
As control, a group of dbydb mice (n 5 9, dbydb-IgG) and
another group of dbym mice (n 5 9, dbym-IgG) received
isotype-matched irrelevant murine IgG. Antibody was adminis-
tered intraperitoneally (300 mg each injection) three times per
week over an 8-wk period, and the animals were killed after 16
wk of age. The antibody treatment regimen was selected on the
basis of previous experiments (12, 34) that involved chronic
administration of monoclonal antibodies and our experiment,
which showed that circulating TGF-b1 levels were significantly
reduced 48 h after i.p. antibody administration (21). Individual
mice were placed in metabolic cages to obtain 24-h urine
collections. Plasma glucose and creatinine and urinary creati-
nine were measured by colorimetric assays (Sigma).
Antibody Preparation. The hybridoma 2G7 cell line, which pro-
duces aT (33), was kindly provided by Brian Fendly (Genentech,
South San Francisco, CA). Large amounts of antibody were
purified by affinity chromatography on Protein G (Charles River
Breeding Laboratories) from the ascitic f luid of naive mice
injected with 2G7 cells. Reactivity of aT was evaluated by using
a mink lung bioassay as previously described (29, 35). Antibody
preparations were sterile filtered and administered intraperito-
neally in buffered saline. The control isotype-matched IgG,
which does not react with TGF-b, was subjected to the same
procedure.
TGF-b1 ELISA. Plasma was obtained as previously described (36).
Retroorbital blood (200 ml) was collected in a siliconized
microfuge tube containing 20 ml of anticoagulant (3.2% sodium
citratey15 mM theophylliney3.7 mM adenosiney0.2 mM dipy-
ridamole; American BioProducts, Parsippany, NJ). Blood was
stored on ice and centrifuged within 30 min at 1,000 3 g at 4°C.
Half the supernatant was transferred to another microfuge tube
by using a siliconized pipette tip, avoiding the interface where
platelets are present, and spun for 2 min at maximum speed to
sediment the platelets. The supernatant was frozen at 220°C
until assayed by a sandwich ELISA kit (Genzyme). Acid acti-
vation of plasma was required to convert latent into active
TGF-b1 that can be recognized by the ELISA antibody. Total
(latent 1 active) TGF-b1 in a sample was compared with known
standards and read as nanogramsymilliliters. The aT adminis-
tered to mice did not interfere with the ELISA antibody (i.e.,
ELISA readings were not affected by the addition of aT to
control plasma at dilutions of 1:10, 1:100, and 1:1,000 as com-
pared with vehicle).
Urine Albumin Assay. Albumin concentrations in 24-h urine sam-
ples were measured with a competitive ELISA (12) in which
mouse albumin in the soluble phase competes with albumin
immobilized onto microtiter wells (250 ngywell) for binding to
horseradish peroxidase-conjugated antialbumin antibody (Exo-
cell, Philadelphia, PA). To avoid errors from an incomplete
urine collection, albumin excretion was normalized to urine
creatinine.
Northern Analysis. Kidney RNA (20 mg) was prepared, electro-
phoresed, transferred to nylon membranes, UV crosslinked, and
prehybridized as described (17). Murine TGF-b type II receptor,
a1(IV) collagen, and fibronectin cDNA probes were synthesized
by PCR by using mouse kidney cDNA as template followed by
cloning in pCRII TA (Invitrogen). Nucleotide sequencing of the
probes confirmed their identities. The cDNA inserts were la-
beled with 32P-deoxycytidine 59-triphosphate (3,000 Ciymmol,
Amersham Pharmacia) by using a DNA labeling kit (Amer-
sham). Procedures for membrane hybridization, high-stringency
washing, and autoradiography were as described (12, 17). Blots
were stripped and rehybridized with a probe encoding mouse
ribosomal protein L32 (mrpL32) to account for loading and
transfer variations. Exposed films were scanned with a laser
densitometer, and RNA levels relative to those of mrpL32 were
calculated.
Immunoblot Analysis. Frozen kidney was homogenized in a lysis
buffer containing 50 mM TriszHCl (pH 8.0), 150 mM NaCl, 1%
Nonidet P-40, 0.1% SDS, 1 mM EDTA, 0.5 mM DTT, 1 mM
PMSF, and 5 mgyml each of aprotinin and leupeptin. Protein was
quantitated by an assay kit (Bio-Rad), electrophoresed (30 mg)
with SDSy12% PAGE, transferred to nitrocellulose membrane,
and blocked with 5% nonfat milk. The membranes were incu-
bated with rabbit antibody directed against TGF-b type II
receptor (Santa Cruz Biotechnology) at room temperature for
3 h. A horseradish peroxidase-conjugated anti-rabbit IgG was
used to detect bands (72 kDa) by using the enhanced chemilu-
minescence detection system (Amersham). Equal loading and
transfer were assessed by staining with Ponceau S. Specificity
was determined by a blocking peptide (Santa Cruz Biotechnol-
ogy). Densitometric analysis was performed as described above.
TGF-b1 Riboprobe Preparation and in Situ Hybridization. The mouse
TGF-b1 cDNA (17) was subcloned into pcDNA3 vector (In-
vitrogen) and linearized with NotI for antisense and HindIII for
sense orientation. The linearized plasmids were gel isolated, and
the transcription reaction for nonisotopic labeling of riboprobe
was performed according to the manufacturer’s instruction
(Boehringer Mannheim). The mixture of digoxigenin labeling
(50 ml) included 1 mg template cDNA, 2 ml NTP labeling
mixture, 2 ml transcription buffer, 1 ml RNase inhibitor, and 2 ml
T7 or SP6 polymerase. Transcription was performed for 2 h at
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37°C followed by digestion with 2 ml RNase-free DNase for 15
min at 37°C. The riboprobe was purified with spin columns. For
in situ hybridization, frozen kidney sections (5 mm) were overlaid
with 30 ml of hybridization buffer containing the labeled RNA
probe and incubated at 58°C overnight in a humid chamber.
After hybridization, sections were washed once in 2 3 SSC at
room temperature, once in 2 3 SSC at 65°C, and once in 0.1 3
SSC at 65°C. Slides were equilibrated with buffer I (100 mM
TriszHCly150 mM NaCl, pH 7.5) for 5 min. Antidigoxigenin
antibody conjugated to alkaline phosphatase (1:5,000) was ap-
plied to the slides and incubated in a humid chamber for 2 h at
room temperature. After two washes in buffer I for 15 min each,
the sections were equilibrated with developing buffer (100 mM
Trisy100 mM NaCly50 mM MgCl2, pH 9.5) for 5 min. The color
reaction was developed by NBTyBCIP (Boehringer) according
to the manufacturer’s instructions. Quantitative evaluation of
the hybridization signal was performed by computer program,
IMAGE-PRO PLUS 3.0 (Media Cybernetics, Silver Spring, MD).
Glomerular Histology and Morphometry. Portions of the renal
cortex were fixed in 10% neutral buffered formalin, embedded
in paraffin, sectioned (3 mm), and stained with periodic acidy
Schiff reagent (PAS). Coded sections were read by an observer
unaware of the experimental protocol. Thirty glomeruli were
randomly selected from each animal, and the extent of extra-
cellular mesangial matrix was identified by PAS-positive material
in the mesangium by using a digital planimeter and factored by
the glomerular tuft area (12).
Statistical Analysis. Data are presented as mean 6 SE, with n the
number of animals. Groups were compared by ANOVA, and
individual groups were compared by the Mann–Whitney test for
unpaired analysis; P , 0.05 was considered significant.
Results
Glomerular TGF-b1 mRNA Localization. To address the question of
whether TGF-b1 expression is preferentially up-regulated within
the glomerular compartment of the diabetic dbydb mouse, in
conjunction with the appearance of glomerulosclerosis, we re-
sorted to nucleic acid in situ hybridization studies. Fig. 1 shows
a selective increase in TGF-b1 mRNA by around 5-fold within
the glomerular tuft (consistent with a mesangial pattern) in
dbydb mice compared with control dbym mice. In our previous
study using Northern analysis of whole-kidney RNA (22), we
demonstrated a slight decrease in total TGF-b1 mRNA, but this
represented a predominant contribution by the tubular epithe-
lium because glomeruli comprise less than 10% of the kidney
parenchyma. On the other hand, expression of the TGF-b type
II receptor in the dbydb mouse kidney is up-regulated in both
tubules and glomeruli (not shown). By Northern analysis and
immunoblotting (Fig. 2), the diabetic state stimulates TGF-b
type II receptor mRNA and protein production in whole-kidney
specimens by more than 2-fold, confirming our previous study
(22). Thus the kidney in the dbydb mouse is characterized by a
selective increase in the glomerular mesangial TGF-b1 mRNA
and a generalized (tubular and glomerular) increase in the
TGF-b type II receptor mRNA.
Clinical Characteristics. The baseline and final characteristics of
the four groups of mice are presented in Table 1. One mouse
from each IgG group died before the completion of the study,
and they were not included in the analysis. As expected, the
initial (age 8 wk) and final (age 16 wk) body weights of dbydb
mice were significantly greater than those of dbym controls. The
increment in weight over time in the dbydb mice was slightly less
in the aT-treated group than in the IgG-treated group. The
diabetic mice remained hyperglycemic throughout the experi-
mental period, and the plasma glucose concentration was slightly
higher in the aT-treated group (Table 1). Because of glycosuria,
urine volumes were markedly increased in both dbydb groups.
Kidney weights were significantly greater in dbydb compared
with dbym mice. By the end of the study, the aT-treated dbydb
mice appeared to have less renal hypertrophy than the IgG-
treated dbydb mice, given the significantly lower kidney weights
in the aT-treated group (Table 1). However, the average kidney-
to-body weight ratios remained unchanged between the aT- and
A B C
D
Fig. 1. Increased glomerular TGF-b1 mRNA in diabetic dbydb mice. In situ
hybridization of kidney sections: (A) antisense TGF-b1 riboprobe in 16-wk-old
control dbym mouse showing minimal hybridization signal; (B) antisense
TGF-b1 riboprobe in 16-wk-old diabetic dbydb mouse showing increased
hybridization signal in the mesangial area; (C) sense TGF-b1 riboprobe used as
negative control in diabetic dbydb mouse showing absence of hybridization
signal; and (D) quantitative analysis of area of TGF-b1 hybridization signal in
dbydb vs. dbym mice. Twenty glomeruli were studied in each group, and the
values presented are the mean 6 SE for four mice in each group. *, P , 0.05
vs. dbym.
Fig. 2. Up-regulation of renal TGF-b type II receptor in dbydb mice. (A)
Representative Northern blot showing increased TGF-b type II receptor mRNA
in dbydb mouse kidney compared with dbym mouse kidney. (B) Summary of
densitometric analyses of receptorymrpL32 mRNA ratios (mean 6 SE, n 5 5 for
each group). The relative ratio in the dbym group is assigned a value of 1. *,
P , 0.05 vs. dbym. (C) Representative immunoblot showing increased TGF-b
type II receptor protein in dbydb mouse kidney compared with dbym mouse
kidney.
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IgG-treated groups, and the ratio was predictably lower in the
dbydb vs. the dbym groups because the diabetic animals were
much heavier. As expected, the obese dbydb mice had consid-
erably greater liver weights than the dbym mice, but the aT-
treated dbydb mice had less liver weight gain compared with the
IgG-treated dbydb mice (Table 1). There were no significant
differences in heart weight among the four groups (not shown),
which may indicate that chronic hypertension did not develop.
Basal plasma TGF-b1 levels in the IgG-treated groups tended
to be higher, but not significantly, in the dbydb mice than in the
dbym mice (Table 1). Confirming the efficacy of the treatment
protocol, the circulating TGF-b1 levels measured 48 h after the
last injection of aT were reduced by 70% in the dbydb mice and
50% in the dbym mice (Table 1). TGF-b2 and TGF-b3 could not
be measured in the plasma, as these isoforms are known to be
undetectable in the circulation (36).
Renal Gene Expression of Matrix Molecules. Renal a1(IV) collagen
mRNA was significantly increased in the IgG-treated diabetic
group compared with the respective nondiabetic group (Fig. 3A).
However, treatment with aT virtually prevented the 8-fold
increase in type IV collagen gene expression in the dbydb mice
(Fig. 3B). Similarly, renal fibronectin mRNA levels were in-
creased more than 4-fold in control dbydb mice but were reduced
to normal values by treatment with aT (Fig. 3 C and D).
Glomerular Histology. At the end of the study, the glomeruli of
dbydb mice demonstrated increased accumulation of PAS-
positive matrix in the mesangium compared with glomeruli of
dbym mice (Fig. 4 C vs. A). Consistent with previous observa-
tions in the dbydb mouse, there were only slight pathological
changes in the tubulointerstitial compartment (not shown).
However, the dbydb mice treated with aT had relatively normal
Table 1. Parameters of the experimental groups of mice
dbym–IgG (n 5 8) dbym–aT (n 5 9) dbydb–IgG (n 5 8) dbydb–aT (n 5 9)
Body wt. initial, g 20.4 6 0.39 21.2 6 0.89 37.1 6 0.56* 37.0 6 0.71*
Body wt. final, g 23.0 6 0.30 23.8 6 1.06 49.6 6 0.66* 46.3 6 0.97†
Plasma glucose, mg/dl 116 6 7 98 6 20 430 6 26* 612 6 16†
Urine volume, ml/day 0.53 6 0.13 0.41 6 0.13 4.33 6 0.56* 3.83 6 0.81*
Kidney wt, mg 127 6 2 138 6 4 194 6 6* 176 6 4*†
Kidney wt/body wt, 3 1023 5.5 6 0.1 5.8 6 0.3 3.9 6 0.2* 3.7 6 0.1*
Liver wt, mg 1022 6 39 1057 6 65 2551 6 75* 2269 6 81*†
Plasma TGF-b1, % control 100 6 5 44 6 9* 134 6 14 49 6 9*†
Plasma creatinine, mgydl 0.34 6 0.02 0.38 6 0.06 0.62 6 0.06* 0.34 6 0.04†
Mice (nondiabetic dbym or diabetic obese dbydb) were treated for 8 wk with either control IgG or neutralizing anti-TGF-b antibody
(aT). Unless specified, parameters were recorded at the end of the experimental period (16 wk of age). wt., weights. *, P , 0.05 vs.
dbym–IgG; †, P , 0.05 vs. dbydb–IgG.
Fig. 3. Kidney matrix gene expression in diabetic mice treated with anti-
TGF-b antibody. A representative Northern blot of kidney RNA probed with
a1(IV) collagen cDNA (A) and fibronectin cDNA (C) and then with ribosomal
mrpL32. Each lane represents RNA from individual mice (dbym or dbydb),
treated with either IgG or anti-TGF-b antibody (aT). Summary of densitometric
analyses of a1(IV) collagenymrpL32 mRNA ratios (B) and fibronectinymrpL32
mRNA ratios (D) in the four treatment groups (mean 6 SE, n 5 8 for each IgG
group and n 5 9 for each aT group). The relative mRNA ratio in the normal-IgG
group is assigned a value of 1. *, P , 0.05 vs. normal-IgG, **, P , 0.05 vs.
diabetic-IgG.
A B
C D
E
Fig. 4. Anti-TGF-b antibody therapy significantly prevents mesangial matrix
expansion in diabetic mice. Representative photomicrographs of PAS-stained
kidney sections from: (A) normal dbym mouse treated with control IgG; (B)
normal dbym mouse treated with anti-TGF-b antibody (aT); (C) diabetic dbydb
mouse treated with control IgG; and (D) diabetic dbydb mouse treated with
aT. Note the diffusely expanded extracellular mesangial matrix in the diabetic
mouse treated with IgG and the marked prevention of this expansion in the
diabetic mouse treated with aT. Quantitative measurement of extracellular
mesangial matrix expansion (E) is expressed as PAS-positive mesangial mate-
rial per total glomerular tuft cross-sectional area. An average value was
obtained from analyses of 30 glomeruli per mouse. Data are mean 6 SE, n 5
8 for each IgG group and n 5 9 for each aT group. *, P , 0.05 vs. normal-IgG,
**, P , 0.05 vs. diabetic-IgG.
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appearing glomeruli (and tubulointerstitium) with minimal mes-
angial matrix expansion compared with dbydb mice treated with
IgG (Fig. 4 D vs. C). Fig. 4E displays the differences in the
fraction of glomerular cross-sectional area occupied by mesan-
gial extracellular matrix, quantitated by glomerular morphom-
etry. The mesangial matrix fraction was increased more than
2.4-fold in diabetic vs. nondiabetic mice, but aT treatment
prevented the increase in the dbydb mice, nearly reaching the
normal value seen in the dbym mice (Fig. 4E).
aT Treatment Prevents Renal Insufficiency. At the onset of interven-
tion (8 wk of age), the plasma creatinine concentration and the
creatinine clearance of the diabetic group were identical to those of
the nondiabetic group (37). By 16 wk of age, the IgG-treated dbydb
mice developed renal insufficiency, as measured by the elevated
plasma creatinine (Table 1) and the reduced creatinine clearance
from 24-h urine collections (Fig. 5A). Treatment with aT com-
pletely prevented the increase in plasma creatinine (Table 1) and
the decrement in creatinine clearance in dbydb mice (Fig. 5A). The
urine albumin excretion was calculated relative to creatinine ex-
cretion to control for possibly incomplete collections. Albumin
excretion rates were significantly increased in dbydb compared with
dbym mice at the conclusion of the study (Fig. 5B). Unlike the other
renal parameters assessed, urine albumin excretion was not lowered
by aT treatment in the diabetic mice (Fig. 5B). It should be noted,
however, that the urinary excretion of albumin factored for the
creatinine clearance was slightly lower in the dbydb mice treated
with aT vs. IgG (not shown). Thus, aT did not have a significant
beneficial effect on the evolution of albuminuria in this mouse
model of diabetes.
Discussion
The dbydb mouse, which expresses a mutant form of the
full-length leptin receptor in the hypothalamus, is a genetic
model of type 2 diabetes mellitus that develops hyperglycemia in
association with insulin resistance and obesity beginning in the
second month of age (31). After 10–20 wk of sustained hyper-
glycemia, it exhibits significant renal pathobiology, including
diffuse glomerulosclerosis (accumulation of mesangial matrix
encroaching the normal capillary network), increased expression
of mRNAs encoding a1(IV) collagen and fibronectin, progres-
sive worsening of proteinuria, and reduction in the glomerular
filtration rate (12, 37). Because the structural and functional
abnormalities, in their evolution and nature, resemble those
observed in human diabetic nephropathy, the dbydb mouse
represents a more suitable model than the STZ diabetic rat for
studying diabetic glomerulosclerosis and examining pathogenic
influences and treatment strategies that may be applicable to the
human disease.
The current study evaluated the role of the renal TGF-b
system in the development of chronic structural and functional
changes of diabetic nephropathy by assessing the response of
dbydb mice to chronic treatment with neutralizing anti-TGF-b
antibodies. In this model, there is a selective increase in glo-
merular mesangial TGF-b1 and a generalized (tubular and
glomerular) up-regulation of the TGF-b type II receptor.
Chronic administration of an antibody that neutralizes the
activity of all three mammalian isoforms of TGF-b resulted in
marked beneficial effects on renal function and structure. De-
spite persistent hyperglycemia, mesangial matrix expansion was
prevented, and the glomerular filtration rate, assessed by plasma
creatinine concentration and creatinine clearance, was pre-
served. These findings strongly suggest that overt nephropathy
was prevented. Progressive expansion of the glomerular mesan-
gial matrix resulting in diffuse intercapillary sclerosis is the most
important structural lesion of diabetic glomerulopathy, because
it correlates closely with the progressive decline in the glomer-
ular capillary surface area available for filtration and hence with
the glomerular filtration rate (38, 39). It is noteworthy that the
anti-TGF-b antibody regimen protected the kidney without
causing any noticeable systemic side effects. Perhaps the circu-
lating TGF-b1 level was sufficiently (see Table 1) but not
excessively reduced to the point that immune responses would be
impaired (40).
The beneficial effects of anti-TGF-b antibody treatment on
reducing mesangial matrix expansion are likely related to neutral-
ization of excess TGF-b1 expression in the glomerular mesangium
and subsequent prevention of extracellular matrix accumulation
(41). In experimental glomerulonephritis, an anti-TGF-b antibody
has been used to demonstrate that the TGF-b system plays an
important role in matrix production (42). In the current study, the
antibody effectively prevented increases in the renal expression of
matrix genes including type IV collagen and fibronectin and may
have also stimulated matrix degradative pathways, because TGF-b
suppresses the activity of metalloproteinases and increases the
expression of protease inhibitors such as plasminogen activator
inhibitor-1 (43). Future studies will be needed to determine
whether anti-TGF-b antibody therapy can be used to reverse
established diabetic nephropathy. The possible mediators of mes-
angial matrix expansion in the dbydb mouse include hyperglycemia
and increased concentrations of Amadori glucose adducts of cir-
culating albumin (7, 12). Correcting hyperglycemia or antagonizing
the effects of Amadori-glycated albumin prevents the pathologic
changes of diabetes in the kidney (12, 44). Moreover, hyperglycemia
and Amadori-glycated albumin activate mesangial cell protein
kinase C (10, 11, 45, 46), up-regulating the TGF-b system and
subsequently stimulating matrix synthesis in these cells (7, 47).
These investigations further prove that increased intrarenal activity
of the TGF-byTGF-b receptor system mediates the fibrogenic
effects of diabetic metabolic changes such as hyperglycemia and
increased glycated albumin.
Our previous study (21), using STZ diabetic mice, has shown
that TGF-b plays an important role in renal hypertrophy, an
early manifestation of diabetes. Neutralization of TGF-b after
only 9 days of treatment prevented glomerular hypertrophy and
markedly reduced total kidney hypertrophy. The current study
Fig. 5. Anti-TGF-b antibody therapy normalizes renal function but not
albuminuria in diabetic mice. (A) Creatinine clearance in normal dbym and
diabetic dbydb groups treated with either IgG or anti-TGF-b antibody (aT).
Clearance was calculated based on urine volumes and plasma and urine
creatinine concentrations. ELISA specific for mouse albumin was used to assess
albuminuria in 24-h urine collections, which was standardized per mg creat-
inine. (B) The increased excretion of albumin in dbydb mice treated with IgG
(vs. dbym mice) remained persistently elevated in dbydb mice treated with aT.
Data are mean 6 SE, n 5 8 for each IgG group and n 5 9 for each aT group.
*, P , 0.05 vs. normal-IgG or normal-aT, **, P , 0.05 vs. diabetic-IgG.
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using dbydb mice reveals that TGF-b also plays a central role in
mesangial matrix expansion and loss of renal function, the late
manifestations of diabetes. Thus, we conclude that blocking the
activity of the renal TGF-b system significantly benefits the
initial as well as the progressive stages of diabetic kidney disease.
Further, TGF-b neutralization therapy can be applied to both
types of diabetes mellitus. These conclusions are supported by
the human findings (23, 24) demonstrating that patients with
either type 1 or type 2 diabetes have up-regulated renal TGF-b
expression before and after the development of nephropathy.
It is important to note that treatment with the anti-TGF-b
antibody did not attenuate the degree of albuminuria in the dbydb
mice despite its beneficial effects on glomerular matrix expansion
and renal function. At first glance, this might suggest that TGF-b
does not play a role in the disturbances that regulate macromolec-
ular permselectivity in diabetes. Albumin permeability is increased
across the glomerular basement membrane in diabetic nephropa-
thy, likely because of hemodynamic stress (48, 49), an increase in the
membrane pore size, a reduction in the anionic charge (50, 51), or
perhaps an increase in the activity of permeability factors such as
vascular endothelial growth factor (VEGF) (52, 53). In this study,
VEGF mRNA was increased 2-fold in dbydb kidneys but anti-
TGF-b antibodies only slightly prevented this increment (not
shown). Studies in cell culture suggest that TGF-b increases VEGF
expression but down-regulates VEGF receptors (52, 53) and does
not reduce the sulfation of glomerular proteoglycans (54). How-
ever, transgenic mice expressing high levels of circulating TGF-b1
still develop glomerular basement membrane thickening and pro-
teinuria (36). Therefore, a longer duration of therapy or more
complete blockade of glomerular TGF-b activity may still reduce
albuminuria. It should be noted that aT treatment preserves the
glomerular filtration rate, and this may need to be accounted for
when assessing the degree of albuminuria. In fact, the urinary
albumin excretion divided by the creatinine clearance was found to
be slightly decreased in the dbydb mice treated with aT vs. IgG.
That aT effectively maintains renal function without decreas-
ing albuminuria seems at first to contradict the prevailing theory
that albuminuria itself promotes progressive renal dysfunction
(55). However, the disparities can be reconciled if one considers
that proteinuria contributes to tubulointerstitial fibrosis via
chemoattractant and prosclerotic mechanisms that mostly in-
volve activation of the TGF-b pathway. Inhibiting the tubuloin-
terstitial TGF-b system with aT thus minimizes the damaging
effects of albuminuria even if it persists.
Diabetic nephropathy is the leading cause of end-stage renal
disease in the industrialized world. Almost 40% of all new
patients with renal failure admitted to renal replacement pro-
grams in the United States have diabetic kidney disease. Ad-
herence to the therapeutic recommendations, such as strict
glycemic and blood pressure control, significantly decreases the
morbidity and mortality associated with this disease. However,
conventional therapies, even when optimally provided, do not
totally halt the progression of diabetic nephropathy. The data we
have provided here strongly support the hypothesis that elevated
intrarenal production or activity of the TGF-byTGF-b receptor
system mediates the functional and structural lesions of overt
diabetic renal disease. The design of new strategies to block the
production or the activity of the renal TGF-b system may
provide a valuable adjunctive therapy for those patients destined
to develop diabetic nephropathy.
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